255 related articles for article (PubMed ID: 16181131)
41. Folate-PEG-NOTA-Al
Chen Q; Meng X; McQuade P; Rubins D; Lin SA; Zeng Z; Haley H; Miller P; González Trotter D; Low PS
Mol Pharm; 2017 Dec; 14(12):4353-4361. PubMed ID: 29028357
[TBL] [Abstract][Full Text] [Related]
42. PET-CT in oncology.
Purandare NC; Rangarajan V
J Postgrad Med; 2010; 56(2):103-8. PubMed ID: 20622389
[TBL] [Abstract][Full Text] [Related]
43. Radiochemical synthesis of 2'-[18F]-labelled and 3'-[18F]-labelled nucleosides for positron emission tomography imaging.
Meyer JP; Probst KC; Westwell AD
J Labelled Comp Radiopharm; 2014 May; 57(5):333-7. PubMed ID: 24692121
[TBL] [Abstract][Full Text] [Related]
44. Clinical molecular imaging with positron emission tomography.
Saleem A; Charnley N; Price P
Eur J Cancer; 2006 Aug; 42(12):1720-7. PubMed ID: 16797972
[TBL] [Abstract][Full Text] [Related]
45. Quantification in positron emission tomography for research in pharmacology and drug development.
Cunningham VJ; Gunn RN; Matthews JC
Nucl Med Commun; 2004 Jul; 25(7):643-6. PubMed ID: 15208489
[TBL] [Abstract][Full Text] [Related]
46. Molecular imaging (PET) of brain tumors.
Basu S; Alavi A
Neuroimaging Clin N Am; 2009 Nov; 19(4):625-46. PubMed ID: 19959009
[TBL] [Abstract][Full Text] [Related]
47. Positron emission tomography (PET): expanding the horizons of oncology drug development.
Hammond LA; Denis L; Salman U; Jerabek P; Thomas CR; Kuhn JG
Invest New Drugs; 2003 Aug; 21(3):309-40. PubMed ID: 14578681
[TBL] [Abstract][Full Text] [Related]
48. Design of radiolabelled ligands for the imaging and treatment of cancer.
Mather SJ
Mol Biosyst; 2007 Jan; 3(1):30-5. PubMed ID: 17216053
[TBL] [Abstract][Full Text] [Related]
49. Development of "[
Jolly D; Hopewell R; Kovacevic M; Li QY; Soucy JP; Kostikov A
Appl Radiat Isot; 2017 Mar; 121():76-81. PubMed ID: 28038410
[TBL] [Abstract][Full Text] [Related]
50. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
51. Positron Emission Tomography (PET) and breast cancer in clinical practice.
Lavayssière R; Cabée AE; Filmont JE
Eur J Radiol; 2009 Jan; 69(1):50-8. PubMed ID: 18814983
[TBL] [Abstract][Full Text] [Related]
52. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.
Robinson MK; Doss M; Shaller C; Narayanan D; Marks JD; Adler LP; González Trotter DE; Adams GP
Cancer Res; 2005 Feb; 65(4):1471-8. PubMed ID: 15735035
[TBL] [Abstract][Full Text] [Related]
53. (124)I in PET imaging: impact on quantification, radiopharmaceutical development and distribution.
Bockisch A; Freudenberg L; Rosenbaum S; Jentzen W
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1247-8. PubMed ID: 16909225
[No Abstract] [Full Text] [Related]
54. Synthesis of oncological [11C]radiopharmaceuticals for clinical PET.
Lodi F; Malizia C; Castellucci P; Cicoria G; Fanti S; Boschi S
Nucl Med Biol; 2012 May; 39(4):447-60. PubMed ID: 22172394
[TBL] [Abstract][Full Text] [Related]
55. [Molecular imaging with new PET tracers].
Beer AJ; Schwaiger M
Radiologe; 2007 Jan; 47(1):8-17. PubMed ID: 17136403
[TBL] [Abstract][Full Text] [Related]
56. Positron emission tomography for use in microdosing studies.
Wagner CC; Müller M; Lappin G; Langer O
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):104-10. PubMed ID: 18175273
[TBL] [Abstract][Full Text] [Related]
57. Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective.
Sager O; Dincoglan F; Demiral S; Uysal B; Gamsiz H; Elcim Y; Gundem E; Dirican B; Beyzadeoglu M
Curr Radiopharm; 2019; 12(1):4-10. PubMed ID: 30465520
[TBL] [Abstract][Full Text] [Related]
58. Radiochemistry for positron emission tomography.
Rong J; Haider A; Jeppesen TE; Josephson L; Liang SH
Nat Commun; 2023 Jun; 14(1):3257. PubMed ID: 37277339
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and preliminary in vivo evaluation of well-dispersed biomimetic nanocrystalline apatites labeled with positron emission tomographic imaging agents.
Sandhöfer B; Meckel M; Delgado-López JM; Patrício T; Tampieri A; Rösch F; Iafisco M
ACS Appl Mater Interfaces; 2015 May; 7(19):10623-33. PubMed ID: 25915450
[TBL] [Abstract][Full Text] [Related]
60. The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease.
Yu M; Nekolla SG; Schwaiger M; Robinson SP
Semin Nucl Med; 2011 Jul; 41(4):305-13. PubMed ID: 21624564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
